



DOCTOR DISCUSSION GUIDE

High-Risk, BCG-unresponsive, Non-Muscle-Invasive Bladder Cancer

STUDY DETAILS:

<https://clinicaltrials.gov/study/NCT04452591>

The BOND-003 study, Cohort P, is currently enrolling patients who have High-Risk, BCG-Unresponsive, papillary-only NMIBC (i.e. High-Grade Ta or T1 disease) without carcinoma in situ (CIS). For your disease to be defined as BCG-Unresponsive, your recurrence must have happened within six months of the last dose of adequate BCG therapy. You must be ineligible or refuse to have a radical cystectomy (bladder removal). All patients will receive cretostimogene in addition to surgical treatment while on study as part of bladder cancer standard of care.

Cretostimogene is an experimental drug and not all risks are known. It is being studied to determine whether it is effective and safe in the treatment of NMIBC.

Cretostimogene will be given intravesically in the bladder using a thin tube called a catheter. Throughout the study, doctors will monitor your health and how your cancer is responding to the treatment.

QUESTIONS TO HELP GUIDE CONVERSATIONS WITH YOUR HEALTHCARE PROFESSIONAL:

- Do I meet the requirements to join this study?
- What will my responsibilities be if I participate?
- What are the possible benefits and risks of participating in this clinical trial?
- Who will oversee my medical care?
- What support/resources does the study team offer to participants and caregivers?
- Can I stop participating in the study after it has begun?

If you would like to learn more about the eligibility requirements of this study, please contact us at:

Recruitment@cgoncology.com